Brief: Marker Therapeutics Provides A Clinical Update On MT-601 In Patients With Lymphoma
19/12/2024 14:13
Dec 19 (Reuters) - Marker Therapeutics Inc MRKR.O :
* MARKER THERAPEUTICS PROVIDES A CLINICAL UPDATE ON MT-601
IN
PATIENTS WITH LYMPHOMA
* MT-601 WELL TOLERATED WITH NO ICANS OBSERVED
Source text: ID:nGNX286lsq
Further company coverage: MRKR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Marker Therapeutics
See all newsBrief: Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant To Advance MT-601 In Pancreatic Cancer
Marker Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Marker Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview
Marker Therapeutics 2025 net loss widens, hurt by decline in grant income
Brief: Marker Therapeutics FY Basic EPS USD -0.79